reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
N-Acetyl Semax
N-Acetyl semax (NA-semax) is an N-acetylated derivative of the Russian-approved nootropic and neuroprotective peptide semax, designed for improved metabolic stability, with no published studies under this specific compound name.
Evidence landscape: 3 published studies
0 published studies under this compound name.
- 3 Other research
Not FDA-approved. Not independently approved by any regulatory authority. The parent compound semax is approved in Russia and Ukraine as a prescription nootropic and neuroprotective agent.
Available as a research compound from peptide suppliers. Not a registered pharmaceutical in any jurisdiction. Properties are inferred from the parent compound semax.
N-acetylated derivative of semax (ACTH(4-10) fragment with Pro-Gly-Pro extension). The N-acetylation is designed to extend the peptide's short half-life by protecting against aminopeptidase degradation. Zero published studies exist under this specific compound name.
PSI Assessment
An N-acetylated derivative of semax designed for improved metabolic stability, N-acetyl semax (NA-semax) has no published studies under this specific compound name. The parent compound semax is approved in Russia and Ukraine as a prescription nootropic, and the N-acetylation modification is intended to extend the peptide's short half-life. Whether the acetylated form retains the parent's nootropic and neuroprotective properties, or whether it introduces pharmacological differences, has not been established in any published research. NA-semax is available in the research peptide market based on inference from semax data, not from direct study of the modified compound.
Zero published studies under this compound name. Properties inferred from the parent compound semax. The modification has not been independently validated.
The theoretical mechanism is identical to semax (ACTH(4-10) fragment, BDNF/NGF upregulation, melanocortin pathway modulation) with improved metabolic stability from N-terminal acetylation. The acetyl group protects against aminopeptidase degradation, theoretically extending the peptide half-life. Whether this modification alters the BDNF/NGF upregulation profile or the neuroprotective efficacy has not been studied.
What the evidence supports
N-acetylation is a well-established pharmaceutical modification for improving peptide stability. The parent compound semax has Russian and Ukrainian regulatory approval with over 200 published studies documenting BDNF upregulation and neuroprotective effects. The structural modification is straightforward.
What is not yet established
Whether NA-semax retains the nootropic and neuroprotective properties of semax. Whether the N-acetylation alters BDNF/NGF upregulation, receptor binding, or clinical effects. Pharmacokinetic profile specific to the acetylated form. Any aspect of safety or efficacy specific to NA-semax.
Research Evidence
No published research exists for NA-semax specifically. The findings below are derived from the parent compound semax.
Evidence by condition
No evidence dimensions can be assessed for NA-semax specifically. All research applies to the parent compound semax. Cognitive enhancement, neuroprotection, and stroke recovery are extrapolated from parent data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cognitive Enhancement | ||||
| Neuroprotection | ||||
| Stroke Recovery |
The parent compound semax has Russian and Ukrainian regulatory approval as a prescription nootropic and neuroprotective agent with over 200 published studies documenting BDNF/NGF upregulation and neuroprotective effects.
All clinical evidence belongs to the parent compound. Whether the N-acetylated derivative retains these properties is entirely unvalidated.
N-acetylation is a well-characterized pharmaceutical modification that protects peptides against aminopeptidase degradation. The modification is expected to extend semax's short half-life based on general peptide chemistry principles.
The pharmacological rationale is sound, but the specific effects on semax's BDNF/NGF upregulation profile, receptor binding, and clinical efficacy have not been studied for the acetylated form.
How N-Acetyl Semax Works
N-Acetyl semax (NA-semax) is a chemically modified version of the peptide semax, with an acetyl group (a small chemical tag) added to its N-terminus (the starting end of the peptide chain). Semax itself is derived from ACTH(4-10), a fragment of a naturally occurring (the body's own) brain hormone called adrenocorticotropic hormone. The acetylation is designed to prevent enzymes from breaking down the peptide too quickly.
Same as Semax. Promotes BDNF production for brain cell health and repair. The N-acetyl group protects the peptide against enzymatic breakdown, potentially extending its activity.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
NA-semax retains the ACTH(4-10) core with Pro-Gly-Pro C-terminal extension and N-terminal acetylation for improved aminopeptidase resistance. Theoretical mechanism: BDNF/NGF upregulation via melanocortin receptor (MC3R/MC4R) modulation, dopaminergic system modulation, and TrkB signaling. Does not affect adrenal steroidogenesis despite the ACTH-derived structure. No pharmacokinetic or pharmacodynamic data exists for the acetylated form specifically.
What is N-Acetyl Semax being studied for?
Researchers are studying N-Acetyl Semax across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for N-Acetyl Semax overall. This means a compound can have human studies for one condition but only animal data for another.
Cognitive Enhancement
·PreclinicalNo published studies for NA-semax specifically. Nootropic effects extrapolated from the parent compound semax, which has Russian regulatory approval.
Limitations: Zero published studies under this compound name. Whether the N-acetylation preserves the nootropic effects of semax is unknown.
Neuroprotection
·PreclinicalNeuroprotective effects extrapolated from semax's BDNF/NGF upregulation. No independent data for the acetylated form.
Limitations: No published neuroprotection studies for NA-semax. Extrapolation from parent compound only.
Stroke Recovery
·PreclinicalStroke recovery effects extrapolated from semax, which is approved in Russia for stroke rehabilitation. No independent data for the acetylated form.
Limitations: No published stroke studies for NA-semax. The parent compound's stroke recovery data cannot be directly attributed to the modified form.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not independently approved by any regulatory authority. The parent compound semax is approved in Russia and Ukraine as a prescription nootropic.
Availability: Available as a research compound from peptide suppliers. Not a registered pharmaceutical. Properties and safety profile are inferred from the parent compound semax.
Class context: No independent safety data for NA-semax. The parent compound semax is well-tolerated in Russian and Ukrainian clinical use. N-acetylation is a common peptide modification that does not typically introduce new toxicity.
NA-semax has no independent safety data. The safety profile is entirely inferred from the parent compound semax, which is well-tolerated in Russian and Ukrainian clinical use. N-acetylation is a standard pharmaceutical modification that does not typically introduce new toxicity, but the specific pharmacokinetics of the acetylated form in humans are unknown.
Questions and Comparisons
Questions the evidence raises for a N-Acetyl Semax discussion.
Comparison and Related Research
NA-semax is most often compared with its parent compound and other Russian-developed neuropeptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational study by the group that developed Semax, investigating protective effects of the parent peptide under hypoxic stress conditions. Demonstrated that Semax improved functional recovery and normalized biochemical markers, establishing the neuroprotective profile that motivated development of the N-acetylated derivative NA-Semax.Antonova SV et al., 1997 in Biull Eksp Biol Med. View on PubMed
- 2.Clinical study evaluating the parent compound Semax in patients with cerebrovascular insufficiency. Treatment reduced the rate of disease progression and exacerbation frequency. NA-Semax was developed as an N-acetylated form of Semax to enhance metabolic stability while preserving these neuroprotective properties.Gusev EI et al., 2005 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 3.Demonstrated that the parent compound Semax increases brain-derived neurotrophic factor (BDNF) and its receptor trkB in the hippocampus, a brain region critical for memory and learning. BDNF supports the survival and growth of neurons, providing a molecular explanation for the cognitive effects reported in clinical studies.Dolotov OV et al., 2006 in Brain Res. View on PubMed
- 4.Investigation of Phase II metabolic pathways including N-acetylation, the chemical modification that distinguishes NA-Semax from its parent compound Semax. N-acetylation is a well-characterized metabolic process that can improve peptide resistance to enzymatic degradation, providing the pharmacological rationale for the N-acetylated derivative.Spriggs S et al., 2018 in Toxicol Lett. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.